Expanding and integrating drug toxicity data and
translational safety intelligence from OFF-X into all aspects of
the life science cycle, allowing customers to make more informed
decisions
LONDON, Aug. 4, 2021 /PRNewswire/ -- Clarivate
Plc (NYSE:CLVT), a global leader in providing trusted information
and insights to accelerate the pace of innovation, today announced
that it has acquired Bioinfogate, a leading provider of
analytics solutions in the life sciences and producer of the
OFF-X™ portal. Financial terms of the transaction were not
disclosed.
The Bioinfogate OFF-X™ portal is a cutting-edge safety
intelligence solution aimed at empowering pharmaceutical
organizations to identify toxicology and safety signals, mitigate
safety liabilities and de-risk early-stage assets. It is one of the
largest translational safety and toxicity portals, featuring over
1,200,000 safety alerts corresponding to over 23,000 drugs and
biologics and more than 15,000 targets of pharmacological
interest.
As a leading provider of trusted information and insights to
accelerate innovation, Clarivate offerings include a comprehensive
suite of research intelligence solutions coupled with deep domain
expertise. The acquisition of Bioinfogate will fill a critical need
for drug toxicity data and translational safety intelligence across
all stages of drug R&D.
This follows a previous acquisition from the Prous family of
companies. Clarivate acquired the Integrity product (now known
as Cortellis Drug Discovery Intelligence™ ) from
Prous Science in 2007. In addition, through a 2019 partnership
with Bioinfogate, Clarivate integrated OFF-X translational
safety intelligence data with Cortellis™ products,
including Cortellis Drug Discovery
and Cortellis Competitive Intelligence™.
In combination with Cortellis, OFF-X will provide critical
translational safety intelligence alongside robust drug pipeline
and clinical research information – allowing biopharma to
seamlessly integrate safety intelligence into preclinical research,
clinical trial planning, regulatory and pharmacovigilance
monitoring, and portfolio strategy. Beyond Cortellis, OFF-X™
will strengthen other Clarivate products and services including the
Web of Science™, the world's most trusted publisher-independent
global citation database.
Mukhtar Ahmed, President,
Science Group, Clarivate: "The acquisition of Bioinfogate will
further our strategy to become an essential provider of solutions
for life science companies along the entire drug development
lifecycle. The combined expertise, data and technologies will help
customers make smarter and faster evidence-based decisions, boost
clinical and commercial success, and bolster our robust integrated
platform of life science intelligence solutions from pre-clinical
and clinical offerings. Ultimately, the acquisition will deepen the
end-to-end value chain from R&D through commercialization and
compensation."
David Prous, Executive Director –
Business Development, Bioinfogate: "This acquisition will be
important to life science firms who need to integrate, access and
apply toxicity and adverse events intelligence across all phases of
drug research and development. The integration of OFF-X into the
Clarivate portfolio of products will further expand and accelerate
the reach of critical drug efficacy and safety information to
researchers around the world."
Josep Prous, Ph.D., Executive Director –
Science, Bioinfogate: "We are pleased to initiate this
synergistic combination of Bioinfogate's safety intelligence
platform with Clarivate science assets. This transaction will be
crucial in advancing safety for patients participating in clinical
trials and beyond while enabling the development of unique
solutions for all those involved in the finding of better and safer
drugs."
Following the successful acquisition and integration of Decision
Resources Group (DRG) in 2020, Clarivate continues to invest in
high-value, real-world data, information and deep subject matter
and technical expertise. Clarivate will continue the tradition of
creating exceptional value for our customers by providing new
offerings focused on further integrating the drug development
information found in Cortellis with OFF-X's translational safety
intelligence. There are strong synergies between the companies that
will strengthen the ability to support customers across the
entire drug lifecycle. The combined business will offer
a one-stop shop for life sciences customers, helping them to
improve the commercialization of life-changing
therapies.
About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate
the lifecycle of innovation. Our bold mission is to help customers
solve some of the world's most complex problems by providing
actionable information and insights that reduce the time from new
ideas to life-changing inventions in the areas of science and
intellectual property. We help customers discover, protect and
commercialize their inventions using our trusted subscription and
technology-based solutions coupled with deep domain expertise. For
more information, please visit clarivate.com.
About Bioinfogate
Bioinfogate is a forward thinking, private company working to solve
unmet medical needs. Its innovative data science products support
the discovery and development of better and safer drugs. Its
capabilities stem from more than 60 years of experience creating
and managing biomedical knowledge, first at Prous Science
(1958-2007), acquired by Thomson Reuters in 2007 (now Clarivate),
and then at Prous Institute for Biomedical Research. Bioinfogate is
the latest initiative within the Prous family group of companies
embracing a long tradition and expertise in scientific knowledge
management.
Forward-Looking Statements
This communication contains "forward-looking statements" as defined
in the Private Securities Litigation Reform Act of 1995. These
statements, which express management's current views concerning
future business, events, trends, contingencies, financial
performance, or financial condition, appear at various places in
this communication and may use words like "aim," "anticipate,"
"assume," "believe," "continue," "could," "estimate," "expect,"
"forecast," "future," "goal," "intend," "likely," "may," "might,"
"plan," "potential," "predict," "project," "see," "seek," "should,"
"strategy," "strive," "target," "will," and "would" and similar
expressions, and variations or negatives of these words. Examples
of forward-looking statements include, among others, statements we
make regarding: guidance outlook and predictions relating to
expected operating results, such as revenue growth and earnings;
strategic actions such as acquisitions, joint ventures, and
dispositions, including the anticipated benefits therefrom, and our
success in integrating acquired businesses; anticipated levels of
capital expenditures in future periods; our ability to successfully
realize cost savings initiatives and transition services expenses;
our belief that we have sufficiently liquidity to fund our ongoing
business operations; expectations of the effect on our financial
condition of claims, litigation, environmental costs, the COVID-19
pandemic and governmental responses thereto, contingent
liabilities, and governmental and regulatory investigations and
proceedings; and our strategy for customer retention, growth,
product development, market position, financial results, and
reserves. Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based only
on management's current beliefs, expectations, and assumptions
regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the
economy, and other future conditions. Because forward-looking
statements relate to the future, they are difficult to predict and
many of which are outside of our control. Important factors that
could cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include those factors discussed under the caption "Risk Factors" in
our most recent annual report on Form 10-K, as amended, along with
our other filings with the U.S. Securities and Exchange Commission
("SEC"). However, those factors should not be considered to
be a complete statement of all potential risks and
uncertainties. Additional risks and uncertainties not known to us
or that we currently deem immaterial may also impair our business
operations. Forward-looking statements are based only on
information currently available to our management and speak only as
of the date of this communication. We do not assume any obligation
to publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by securities and other applicable laws. Please
consult our public filings with the SEC or on our website
at www.clarivate.com.
Media Contact
Tabita Seagrave, Head of Global
Corporate Communications
tabita.seagrave@clarivate.com
Investor Relations Contact
Mark Donohue, Head of Investor
Relations
Mark.donohue@clarivate.com
(215) 243-2202
View original
content:https://www.prnewswire.com/news-releases/clarivate-acquires-bioinfogate-reinforcing-position-as-premier-provider-of-end-to-end-research-intelligence-solutions-for-life-sciences-301347961.html
SOURCE Clarivate Plc